SPI Pharma and Inimmune Partner on Vaccine Adjuvant Development

• SPI Pharma and Inimmune Corp. partner to develop advanced adjuvant systems for vaccines.

• The collaboration combines expertise in adjuvant formulation and commercial capabilities to enhance vaccine efficacy.

SPI Pharma and Inimmune Corp. have announced a partnership to develop and commercialise advanced adjuvant systems for vaccine development. The collaboration leverages Inimmune’s expertise in adjuvant formulation and immunotherapeutics alongside SPI Pharma’s manufacturing and global commercial capabilities.

Adjuvant systems are critical for enhancing the immune response and efficacy of vaccines. This partnership aims to address unmet needs in vaccine development by ensuring a reliable supply of advanced adjuvant systems. The goal is to accelerate the availability of these technologies to healthcare providers and patients worldwide.

“Inimmune’s dedication to advancing immunological research coupled with SPI Pharma’s robust commercial infrastructure creates a powerful synergy,” said John McInerney, Vice President of Commercial for SPI Pharma. “Together, we are poised to deliver innovative solutions that can potentially transform vaccine efficacy and patient outcomes worldwide.”

Alan Joslyn, Ph.D., CEO of Inimmune, expressed similar enthusiasm about the collaboration. “We are excited to collaborate with SPI Pharma to bring our vaccine adjuvant technologies to market,” Joslyn said. “This partnership underscores our shared commitment to improving public health through innovation.”